Genetic polymorphism and current biotechnology approaches of therapeutic aspects within endometrial tumors

Among oncological diseases of women, gynecological diseases deserve special attention. Gynecological tumors are important to women's health throughout the world. Notably, gynecologic malignancies represent a prevalent category of cancers affecting women globally. Single nucleotide polymorphisms have emerged as a promising source of genetic information to better understand complex diseases such as cancer, in terms of etiology, interindividual differences and treatment response. In this review, we summarize some selected gene single nucleotide polymorphisms’ implication in gynecological cancer susceptibility/predisposition, as well as the potential to use such genetic markers for improved diagnosis and individualized treatment of gynecological cancers. Furthermore, this review explores the advances in biotechnology that have contributed to the management of gynecological tumors, in particular endometrial tumors, with a focus on molecular diagnostics, therapeutic innovations, and personalized medicine. It is critical to investigate the single nucleotide gene polymorphisms as sociated with gynecologic cancer susceptibility/predisposition as some of them might be utilized as useful molecular markers for assessing gynecologic cancer predisposition and might be further used for diagnosis and treatment modalities in individuals with similar single nucleotide polymorphism profile. Moreover, recent advancements in biosensing technologies, particularly nano-biosensors and microfluidic biosensors, have significantly enhanced the detection of gynecological tumor markers. Taken together, the revolution in cancer research, diagnosis, and treatment has been made possible by advances in biotechnology in recent decades.